skip to Main Content

Reassurance over treatments and Brexit

  • 21 December 2020
We have spoken to Roche, Novartis Gene Therapies and Biogen about the continued supply of treatments for Spinal Muscular Atrophy. All three companies have clearly indicated that over the past 2 years they were preparing for various outcomes of Brexit negotiations, including a no deal option. As a result of those preparations there is now a suitable reserve of stock for the treatments and no disruption is foreseen.
Read More

How did we do it and is it safe?

  • 11 December 2020

This is a question many people asking about the Covid-19 vaccine considering it was approved so quickly. MHRA chief executive explains the process in the article below to reassure.

Read More

Cambridge University Hospitals denies free life-saving treatment due to age, for the second time!

  • 28 November 2020

Cambridge University Hospitals (CUH) is regarded as one of the most reputable medical institutions worldwide and provides specialist services to many conditions nationally and internationally, including being a Neuromuscular Centre of Excellence as awarded by MDUK. Therefore, it begs the question, why, when the FDA, MHRA and most other Neuromuscular Centres across the country are prescribing risdiplam to patients of all ages, does CUH feel able to have a different opinion to all of these experts?

Read More
Back To Top